Restoring host antitumoral immunity: How coregulatory molecules are changing the approach to the management of renal cell carcinoma

Brant A. Inman, Xavier Frigola, Haidong M Dong, James C. Yang, Eugene D Kwon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Renal cell carcinoma (RCC) is a tumor whose past is filled with failed treatments and unpreventable patient death. Fortunately, science is progressing at an ever increasing rate and novel discoveries are bringing new possibilities for patients with RCC. The future of RCC treatment is bright, and we believe that immunotherapy will realize much of its potential within the next decade. In this chapter, we discuss one of the newest discoveries in RCC tumor immunology: T-cell coinhibition. This chapter will first introduce key concepts of T-cell function and tumor immunology that are necessary for a good understanding of how coinhibition works. We then describe some of the key defects in immunity that are present in RCC. Finally, we propose a model to explain why certain renal tumors are eliminated by the immune system and others are not.

Original languageEnglish (US)
Title of host publicationRenal Cell Carcinoma: Molecular Targets and Clinical Applications
PublisherHumana Press
Pages367-403
Number of pages37
ISBN (Print)9781588297372
DOIs
StatePublished - 2009

Fingerprint

Renal Cell Carcinoma
Immunity
Allergy and Immunology
Neoplasms
T-Lymphocytes
Immunotherapy
Immune System
Kidney
Therapeutics

Keywords

  • Coinhibition
  • Costimulation
  • Immunoediting
  • Immunotherapy
  • Renal cell carcinoma
  • T lymphocyte
  • Tumor immunology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Inman, B. A., Frigola, X., Dong, H. M., Yang, J. C., & Kwon, E. D. (2009). Restoring host antitumoral immunity: How coregulatory molecules are changing the approach to the management of renal cell carcinoma. In Renal Cell Carcinoma: Molecular Targets and Clinical Applications (pp. 367-403). Humana Press. https://doi.org/10.1007/978-1-59745-332-5_21

Restoring host antitumoral immunity : How coregulatory molecules are changing the approach to the management of renal cell carcinoma. / Inman, Brant A.; Frigola, Xavier; Dong, Haidong M; Yang, James C.; Kwon, Eugene D.

Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, 2009. p. 367-403.

Research output: Chapter in Book/Report/Conference proceedingChapter

Inman, BA, Frigola, X, Dong, HM, Yang, JC & Kwon, ED 2009, Restoring host antitumoral immunity: How coregulatory molecules are changing the approach to the management of renal cell carcinoma. in Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, pp. 367-403. https://doi.org/10.1007/978-1-59745-332-5_21
Inman BA, Frigola X, Dong HM, Yang JC, Kwon ED. Restoring host antitumoral immunity: How coregulatory molecules are changing the approach to the management of renal cell carcinoma. In Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press. 2009. p. 367-403 https://doi.org/10.1007/978-1-59745-332-5_21
Inman, Brant A. ; Frigola, Xavier ; Dong, Haidong M ; Yang, James C. ; Kwon, Eugene D. / Restoring host antitumoral immunity : How coregulatory molecules are changing the approach to the management of renal cell carcinoma. Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press, 2009. pp. 367-403
@inbook{435ad21f22da4e5586d5747ae7899db0,
title = "Restoring host antitumoral immunity: How coregulatory molecules are changing the approach to the management of renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is a tumor whose past is filled with failed treatments and unpreventable patient death. Fortunately, science is progressing at an ever increasing rate and novel discoveries are bringing new possibilities for patients with RCC. The future of RCC treatment is bright, and we believe that immunotherapy will realize much of its potential within the next decade. In this chapter, we discuss one of the newest discoveries in RCC tumor immunology: T-cell coinhibition. This chapter will first introduce key concepts of T-cell function and tumor immunology that are necessary for a good understanding of how coinhibition works. We then describe some of the key defects in immunity that are present in RCC. Finally, we propose a model to explain why certain renal tumors are eliminated by the immune system and others are not.",
keywords = "Coinhibition, Costimulation, Immunoediting, Immunotherapy, Renal cell carcinoma, T lymphocyte, Tumor immunology",
author = "Inman, {Brant A.} and Xavier Frigola and Dong, {Haidong M} and Yang, {James C.} and Kwon, {Eugene D}",
year = "2009",
doi = "10.1007/978-1-59745-332-5_21",
language = "English (US)",
isbn = "9781588297372",
pages = "367--403",
booktitle = "Renal Cell Carcinoma: Molecular Targets and Clinical Applications",
publisher = "Humana Press",

}

TY - CHAP

T1 - Restoring host antitumoral immunity

T2 - How coregulatory molecules are changing the approach to the management of renal cell carcinoma

AU - Inman, Brant A.

AU - Frigola, Xavier

AU - Dong, Haidong M

AU - Yang, James C.

AU - Kwon, Eugene D

PY - 2009

Y1 - 2009

N2 - Renal cell carcinoma (RCC) is a tumor whose past is filled with failed treatments and unpreventable patient death. Fortunately, science is progressing at an ever increasing rate and novel discoveries are bringing new possibilities for patients with RCC. The future of RCC treatment is bright, and we believe that immunotherapy will realize much of its potential within the next decade. In this chapter, we discuss one of the newest discoveries in RCC tumor immunology: T-cell coinhibition. This chapter will first introduce key concepts of T-cell function and tumor immunology that are necessary for a good understanding of how coinhibition works. We then describe some of the key defects in immunity that are present in RCC. Finally, we propose a model to explain why certain renal tumors are eliminated by the immune system and others are not.

AB - Renal cell carcinoma (RCC) is a tumor whose past is filled with failed treatments and unpreventable patient death. Fortunately, science is progressing at an ever increasing rate and novel discoveries are bringing new possibilities for patients with RCC. The future of RCC treatment is bright, and we believe that immunotherapy will realize much of its potential within the next decade. In this chapter, we discuss one of the newest discoveries in RCC tumor immunology: T-cell coinhibition. This chapter will first introduce key concepts of T-cell function and tumor immunology that are necessary for a good understanding of how coinhibition works. We then describe some of the key defects in immunity that are present in RCC. Finally, we propose a model to explain why certain renal tumors are eliminated by the immune system and others are not.

KW - Coinhibition

KW - Costimulation

KW - Immunoediting

KW - Immunotherapy

KW - Renal cell carcinoma

KW - T lymphocyte

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=84891965427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891965427&partnerID=8YFLogxK

U2 - 10.1007/978-1-59745-332-5_21

DO - 10.1007/978-1-59745-332-5_21

M3 - Chapter

AN - SCOPUS:84891965427

SN - 9781588297372

SP - 367

EP - 403

BT - Renal Cell Carcinoma: Molecular Targets and Clinical Applications

PB - Humana Press

ER -